摘要
目的探讨细胞因子诱导的杀伤细胞(CIK)联合小剂量白介素2(IL-2)治疗恶性体腔积液的疗效及对免疫指标的影响。方法选取2008年1月1日至2012年12月1日收治的143例恶性体腔积液患者,采用CIK细胞联合小剂量IL-2治疗的67例患者为观察组,单独采用IL-2治疗的76例患者为对照组。对比两组患者的临床疗效和免疫指标变化。结果观察组患者临床有效率为79.1%,对照组临床有效率为61.8%,差异有统计学意义(P<0.05)。两组患者治疗前免疫指标CD+3、CD+4、CD+4/CD+8和NK细胞差异无统计学意义(P>0.05)。治疗后所有患者免疫指标均明显高于治疗前,组间比较显示,治疗后观察组患者的免疫指标水平均高于对照组患者,差异有统计学意义(P<0.05)。结论 CIK细胞联合小剂量IL-2治疗恶性体腔积液的疗效显著,症状发作和体腔积液明显较少,可以明显升高CD+3、CD+4、CD+4/CD+8和NK细胞等免疫指标水平。
Objective To investigate the efficacy and immune parameters impact of CIK cell combined with low dose interleukin-2 in the treatment on malignant body cavity effusion.Methods The vicious body cavity effusion patients admitted in our hospital from Jan 2008 to Dec 2012 were selected in the research.67 cases of patients were selected as observation group to take CIK cells combined with low dose interleukin-2 treatment,and the 76 cases of patients were selected to take interleukin-2 alone as the treatment.By comparing the changes of clinical efficacy and immune indices,the clinical efficacy and immune indices of CIK cell combined with low dose interleukin-2 treatment for malignant body cavity effnsion was investigated.Results The clinical efficiency of the observation group is significantly better than the control group.In the comparison of immune indices,the differences of CD+ 3,CD+ 4,CD+ 4 / CD+ 8 and NK between the tow groups before treatment is not significant(P 0.05).The immune indices of the patients after treatment are significantly higer than the patients before the treatment.From the comparison between the two groups,the immnue indices of observation group is significantly higher than the cntrol group after the treatment,which is statistically significant(P 0.05).Conclusions Significant efficacy is showed for CIK cell combined with low dose interleukin-2 in the treatment of malignant body cavity,the onset of symptoms and body cavity effusion is significantly less.Moreover,this method can significantly improve the immune indices level of CD+ 3,CD+ 4,CD+ 4 / CD+ 8 and NK cell.
出处
《中国肿瘤临床与康复》
2013年第8期861-863,共3页
Chinese Journal of Clinical Oncology and Rehabilitation